MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate several intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Major trial objectives had been to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, when one of the expl... https://peterr887cny0.wikigop.com/user